Agilisium, a life sciences company, has announced plans to shift its Asia headquarters to Hyderabad, strengthening the city’s position as a base for technology-led life sciences operations. The company said the decision recognises Telangana’s growing prominence in the global life sciences sector.
The announcement was made by Agilisium in a company release. Founder and chief executive officer Raj Babu said India had demonstrated its ability to build globally competitive technology businesses, and that the next opportunity was to combine this strength with scientific expertise, deep industry knowledge and proprietary intellectual property.
“India has proven its ability to build globally competitive technology businesses. The next opportunity is to combine this strength with scientific expertise, deep industry knowledge and proprietary IP to transform global industries,” Babu said.
Agilisium’s planned headquarters shift places Hyderabad at the centre of the company’s Asia operations as it expands its focus on artificial intelligence and technology services for the life sciences sector. The company said its work spans research and drug discovery, clinical development, manufacturing and commercial operations.
Arun Kumar, Agilisium’s chief operating officer and chief AI and innovation officer, said the company was investing in talent, proprietary AI platforms and delivery models. He said the relocation would strengthen Agilisium’s commitment to developing differentiated intellectual property and delivering measurable business value.
“AI in Life Sciences depends on bringing together scientific expertise, deep domain context and intelligent technology to solve complex industry challenges,” Kumar said. “At Agilisium, we are investing in talent, proprietary AI platforms and delivery models. The planned relocation of our Asia headquarters to Hyderabad strengthens our commitment to building differentiated intellectual property and delivering measurable business value.”
The company entered the life sciences sector in 2018 and has since built capabilities across the sector’s main operating stages, from research and drug discovery to clinical development, manufacturing and commercial functions. The proposed relocation therefore links Hyderabad not only to Agilisium’s corporate administration but also to its technology and delivery activities in a specialised industry.
Agilisium said it was on track to close 2026 with revenue of $72 million to $75 million. The company did not specify in the announcement when the headquarters shift would be completed, how many employees would be based in Hyderabad or the precise location of the new Asia headquarters. The next formal milestones will depend on the company’s implementation plans for the relocation.
